S1094
Clinical – Upper GI
ESTRO 2026
with esophageal cancer, warranting prospective validation. References: 1. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167-74.2. Hulshof MCCM, Geijsen ED, Rozema T, et al. Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study). J Clin Oncol 2021;39:2816-24.3. Fan XW, Wang HB, Mao JF, et al. Sequential boost of intensity-modulated radiotherapy with chemotherapy for inoperable esophageal squamous cell carcinoma: A prospective phase II study. Cancer Med 2020;9:2812-9. Keywords: esophageal, chemoradiotherapy, dose escalation Ten year real-world analysis of Stereotactic Body Radiation Therapy (SBRT) in the management of hepatocellular carcinoma Veronica Vernier 1 , Lorenzo Lo Faro 1 , Tiziana Comito 1 , Sara Stefanini 1 , Marie Lohmer 1,2 , Andrea Bresolin 1 , Pietro Mancosu 1,2 , Ciro Franzese 1,2 , Marta Scorsetti 1,2 1 Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, Rozzano, Italy. 2 Biomedical sciences, Humanitas University, Pieve Emanuele, Italy Purpose/Objective: Stereotactic body radiation therapy (SBRT) has emerged as an effective and well-tolerated local treatment for hepatocellular carcinoma (HCC), achieving high local control rates with minimal invasiveness. This study retrospectively evaluated the long-term clinical outcomes, safety profile, and prognostic factors of patients with HCC treated with SBRT in a real-world setting over the past decade. Material/Methods: Patients with histologically or radiologically confirmed HCC who underwent liver SBRT between June 2013 and December 2024 were retrospectively analyzed. Digital Poster Highlight 3169 Data were collected from institutional databases derived from routine clinical practice, with follow-up extended until July 31, 2025. Different dose- fractionation schemes were adopted according to patient and tumor characteristics. Patients receiving palliative doses or lacking institutional follow-up were excluded. Primary endpoints included local control (LC), progression-free survival (PFS), overall survival (OS), and treatment-related toxicity. Survival outcomes were calculated using the Kaplan–Meier method, and prognostic factors were evaluated by univariate and multivariate analyses.
Conclusion: In this large retrospective Asian cohort, radiation dose escalation beyond 50.4 Gy was associated with improved LRFS, PFS, and OS. These findings indicate a potential benefit of dose escalation for Asian patients
Made with FlippingBook - Share PDF online